Efficacy of Colchicine in Reducing NT-proBNP, Caspase-1, TGF-β, and Galectin-3 Expression and Improving Echocardiography Parameters in Acute Myocardial Infarction: A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial DOI Open Access

Tri Astiawati,

Mohammad Saifur Rohman, Titin Andri Wihastuti

и другие.

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(4), С. 1347 - 1347

Опубликована: Фев. 18, 2025

Background: Caspase-1 (reflects NOD-like receptor protein 3 inflammasome activity), transforming growth factor-β (TGF-β), and Galectin-3 play significant roles in post-AMI fibrosis inflammation. Recently, colchicine was shown to dampen inflammation after AMI; however, its direct benefit remains controversial. Objectives: This study aimed analyze the of reducing NT-proBNP, Caspase-1, TGF-β,and expression improving systolic-diastolic echocardiography parameters among AMI patients. Methods: A double-blinded, placebo-controlled, randomized, multicenter clinical trial conducted at three hospitals East Java, Indonesia: Dr. Saiful Anwar Hospital Malang, Soebandi Jember, Iskak Tulungagung, between 1 June 31 December 2023. total 161 eligible subjects were randomly allocated 1:1 (0.5 mg daily) or standard treatment for 30 days. TGF-β, tested on day 5 by ELISA, while NT-proBNP days 30. Transthoracic also performed Results: By 30, no improvements had been group. However, reduced level more than placebo (ΔNT-proBNP: -73.74 ± 87.53 vs. -75.75 12.44 pg/mL; p < 0.001). Moreover, lowered levels TGF-β 1. Conclusions: Colchicine can reduce significantly administration capable inflammation, ventricular dysfunction, heart failure but did not improve (ClinicalTrials.gov identifier: NCT06426537).

Язык: Английский

Efficacy of Colchicine in Reducing NT-proBNP, Caspase-1, TGF-β, and Galectin-3 Expression and Improving Echocardiography Parameters in Acute Myocardial Infarction: A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial DOI Open Access

Tri Astiawati,

Mohammad Saifur Rohman, Titin Andri Wihastuti

и другие.

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(4), С. 1347 - 1347

Опубликована: Фев. 18, 2025

Background: Caspase-1 (reflects NOD-like receptor protein 3 inflammasome activity), transforming growth factor-β (TGF-β), and Galectin-3 play significant roles in post-AMI fibrosis inflammation. Recently, colchicine was shown to dampen inflammation after AMI; however, its direct benefit remains controversial. Objectives: This study aimed analyze the of reducing NT-proBNP, Caspase-1, TGF-β,and expression improving systolic-diastolic echocardiography parameters among AMI patients. Methods: A double-blinded, placebo-controlled, randomized, multicenter clinical trial conducted at three hospitals East Java, Indonesia: Dr. Saiful Anwar Hospital Malang, Soebandi Jember, Iskak Tulungagung, between 1 June 31 December 2023. total 161 eligible subjects were randomly allocated 1:1 (0.5 mg daily) or standard treatment for 30 days. TGF-β, tested on day 5 by ELISA, while NT-proBNP days 30. Transthoracic also performed Results: By 30, no improvements had been group. However, reduced level more than placebo (ΔNT-proBNP: -73.74 ± 87.53 vs. -75.75 12.44 pg/mL; p < 0.001). Moreover, lowered levels TGF-β 1. Conclusions: Colchicine can reduce significantly administration capable inflammation, ventricular dysfunction, heart failure but did not improve (ClinicalTrials.gov identifier: NCT06426537).

Язык: Английский

Процитировано

0